Physician

Thomas J. Langei, MD

According to 2025 Medicare claims, Thomas Langei, MD (NPI: 1528180015) practices dermatology in the Bellingham, WA market, with the plurality of this provider's patient population coming from Whatcom, WA. This provider's primary affiliated billing organization is FAIRHAVEN DERMATOLOGY, PLLC (NPI: 1336693902; TIN: 812592461) and primary practice location at 98225-8212.

Langei's data goes back to 2015 and runs through 2024. For example, in 2024, this provider had 702 traditional Medicare patients, billed 2,206 HCPCS/CPT codes, and received $618,803 in Medicare payments. The top billing code was 17311 (Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks). Part D data shows 246 prescription claims across 180 beneficiaries totaling $4,076 in drug costs, led by Imiquimod (Imiquimod). No Open Payments records. You can download detailed data with all billing codes (2015-2024). For more recent data, please contact us.

Over the past 10 years, this provider's Medicare Part B carrier billing did not follow a clear longitudinal pattern. Concurrently, Part D prescription costs started with an early spike, then settled into a lower baseline, moving from $70,064 to $4,076. For DME billing, this provider has fewer than 5 years of reported data, so a reliable trend cannot be assigned.

Part B Carrier Billing Trend

Medicare payment trend, with N of patients and claim lines in the table.

Part B Carrier Billing Trend. X-axis: year 2015-2024. Y-axis: Medicare payment, unit: USD. Field: Tot_Mdcr_Pymt_Amt. Source: Medicare Physician & Other Practitioners by Provider.0$354K$707K2015 Medicare payment: $305,055 (USD; Tot_Mdcr_Pymt_Amt)2016 Medicare payment: $344,869 (USD; Tot_Mdcr_Pymt_Amt)2017 Medicare payment: $668,324 (USD; Tot_Mdcr_Pymt_Amt)2018 Medicare payment: $635,941 (USD; Tot_Mdcr_Pymt_Amt)2019 Medicare payment: $707,415 (USD; Tot_Mdcr_Pymt_Amt)2020 Medicare payment: $705,113 (USD; Tot_Mdcr_Pymt_Amt)2021 Medicare payment: $679,833 (USD; Tot_Mdcr_Pymt_Amt)2022 Medicare payment: $644,229 (USD; Tot_Mdcr_Pymt_Amt)2023 Medicare payment: $636,639 (USD; Tot_Mdcr_Pymt_Amt)2024 Medicare payment: $618,803 (USD; Tot_Mdcr_Pymt_Amt)2015201620172018201920202021202220232024
YearPatientsClm LinesPayment
20158834,850$305,055
20168083,714$344,869
20177824,312$668,324
20187813,854$635,941
20198813,871$707,415
20208893,442$705,113
20217802,584$679,833
20227332,361$644,229
20237422,424$636,639
20247022,206$618,803

Part D Events Trend

Drug cost trend, with N of patients and prescription claims in the table.

Part D Events Trend. X-axis: year 2015-2024. Y-axis: Drug cost, unit: USD. Field: Tot_Drug_Cst. Source: Medicare Part D Prescribers by Provider.0$35K$70K2015 Drug cost: $70,064 (USD; Tot_Drug_Cst)2016 Drug cost: $20,282 (USD; Tot_Drug_Cst)2017 Drug cost: $5,346 (USD; Tot_Drug_Cst)2018 Drug cost: $6,751 (USD; Tot_Drug_Cst)2019 Drug cost: $4,627 (USD; Tot_Drug_Cst)2020 Drug cost: $6,147 (USD; Tot_Drug_Cst)2021 Drug cost: $4,723 (USD; Tot_Drug_Cst)2022 Drug cost: $3,728 (USD; Tot_Drug_Cst)2023 Drug cost: $3,343 (USD; Tot_Drug_Cst)2024 Drug cost: $4,076 (USD; Tot_Drug_Cst)2015201620172018201920202021202220232024
YearPatientsClaimsDrug Cost
2015210455$70,064
2016155295$20,282
2017159221$5,346
2018158230$6,751
2019173239$4,627
2020239329$6,147
2021209272$4,723
2022161210$3,728
2023156199$3,343
2024180246$4,076

DME Billing Trend

Medicare payment trend, with N of patients and DME claim records in the table.

No connected DME records

No connected DME records

* / # = suppressed by CMS; 0 = reported zero; N/R = not reported or blank.

Top 5 Part B carrier billing codes in 2024

By total payments.

CodeDescriptionPatientsClm LinesTotal Payment
17311Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, 1-5 tissue blocks500619$489
17312Removal and microscopic exam of growth of head, neck, hands, feet, or genitals, each additional stage, 1-5 tissue blocks168253$342
13132Complicated repair of wound of forehead, cheeks, chin, mouth, neck, underarms, genitals, hands, or feet, 2.6-7.5 cm139143$198
11102Biopsy of related skin growth, first growth7482$53
17000Destruction of precancer skin growth, 1 growth6170$32

Top 5 Part D drugs in 2024

By total drug costs.

DrugGenericClaimsTotal Day SupplyTotal Drug Cost
ImiquimodImiquimod411,119$1,245
FluorouracilFluorouracil17521$866
Minocycline HclMinocycline Hcl68482$598
MupirocinMupirocin711,568$543
CephalexinCephalexin1177$169

Top 5 DME services in 2024

No connected or detailed DME service-level records for 2024.

Open Payments Summary

No connected Open Payments records were found for this physician in General Payments, Research Payments, or Ownership / Investment Interests.

FAQ

What Medicare data is available for Thomas J. Langei, MD?

Tedicare shows public-source Medicare data for Thomas J. Langei, MD (NPI 1528180015), including provider identity, specialty, market context, Medicare Part B activity, Part D prescribing, DME records, Open Payments where available, billing organization details, and ACO affiliation signals where available. Profile data covers 2015-2024, with current attribution based on 2025 claims where available.

Does Thomas J. Langei, MD have ACO affiliation data?

No ACO affiliation record is shown in the available Tedicare data for this profile.

What billing organization is linked to Thomas J. Langei, MD?

Thomas J. Langei, MD is linked to FAIRHAVEN DERMATOLOGY, PLLC (billing NPI 1336693902) in the available physician profile data.

Does Thomas J. Langei, MD have Open Payments data?

No connected Open Payments records are shown for this physician in the available General Payments, Research Payments, or Ownership / Investment Interests data.

Can I download physician-level Medicare data from Tedicare?

Yes. Tedicare provides sample physician export data and paid custom physician data exports for research, planning, outreach, and market analysis. Exports can include physician profile fields, market and specialty context, billing organization details, ACO affiliation signals where available, and Medicare utilization data.